» Articles » PMID: 26510186

The Effect of Neutral Peritoneal Dialysis Solution with Low Glucose-Degradation-Product on the Fluid Status and Body Composition--A Randomized Control Trial

Overview
Journal PLoS One
Date 2015 Oct 29
PMID 26510186
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Previous studies report conflicting results on the benefit of peritoneal dialysis (PD) patients treated with low glucose degradation product (GDP) solution. The effects of low GDP solution on body fluid status and arterial pulse wave velocity (PWV) have not been studied.

Methods: We randomly assigned 68 incident PD patients to low GDP (Intervention Group) or conventional solutions (Control Group); 4 dropped off before they received the assigned treatment. Patients were followed for 52 weeks for changes in ultrafiltration, residual renal function, body fluid status and arterial PWV.

Result: After 52 weeks, Intervention Group had higher overhydration (3.1 ± 2.6 vs 1.9 ± 2.2 L, p = 0.045) and extracellular water volume (17.7 ± 3.9 vs 15.8 ± 3.1 L, p = 0.034) than Control Group. There was no significant difference in PWV between groups. There was no significant difference in residual renal function between the Groups. Intervention Group had lower ultrafiltration volume than Control Group at 4 weeks (0.45 ± .0.61 vs 0.90 ± 0.79 L/day, p = 0.013), but the difference became insignificant at later time points. Intervention Group had lower serum CRP levels than Control Group (4.17 ± 0.77 vs 4.91 ± 0.95 mg/dL, p < 0.0001).

Conclusion: Incident PD patients treated with low GDP solution have less severe systemic inflammation but trends of less ultrafiltration, and more fluid accumulation. However, the effects on ultrafiltration and fluid accumulation disappear with time. The long term effect of low GDP solution requires further study.

Trial Registration: ClinicalTrials.gov NCT00966615.

Citing Articles

Dialysis Duration and Glucose Exposure Amount Do Not Increase Mortality Risk in Peritoneal Dialysis Patients: A Population-Based Cohort Study From 2004 to 2012.

Wu P, Lin M, Hwang S, Chiu Y Front Med (Lausanne). 2022; 9:897545.

PMID: 35836946 PMC: 9273817. DOI: 10.3389/fmed.2022.897545.


Biocompatible dialysis fluids for peritoneal dialysis.

Htay H, Johnson D, Wiggins K, Badve S, Craig J, Strippoli G Cochrane Database Syst Rev. 2018; 10:CD007554.

PMID: 30362116 PMC: 6517187. DOI: 10.1002/14651858.CD007554.pub3.


Peritoneal dialysis-related peritonitis caused by Pseudomonas species: Insight from a post-millennial case series.

Lu W, Kwan B, Chow K, Pang W, Leung C, Li P PLoS One. 2018; 13(5):e0196499.

PMID: 29746497 PMC: 5944923. DOI: 10.1371/journal.pone.0196499.


Is there such a thing as biocompatible peritoneal dialysis fluid?.

Peter Schmitt C, Aufricht C Pediatr Nephrol. 2016; 32(10):1835-1843.

PMID: 27722783 PMC: 5579143. DOI: 10.1007/s00467-016-3461-y.

References
1.
FORBES G, Bruining G . Urinary creatinine excretion and lean body mass. Am J Clin Nutr. 1976; 29(12):1359-66. DOI: 10.1093/ajcn/29.12.1359. View

2.
Schmitt C, Haraldsson B, Doetschmann R, Zimmering M, Greiner C, Boswald M . Effects of pH-neutral, bicarbonate-buffered dialysis fluid on peritoneal transport kinetics in children. Kidney Int. 2002; 61(4):1527-36. DOI: 10.1046/j.1523-1755.2002.00255.x. View

3.
Liberek T, Topley N, Jorres A, Petersen M, Coles G, Gahl G . Peritoneal dialysis fluid inhibition of polymorphonuclear leukocyte respiratory burst activation is related to the lowering of intracellular pH. Nephron. 1993; 65(2):260-5. DOI: 10.1159/000187485. View

4.
Enia G, Sicuso C, Alati G, Zoccali C . Subjective global assessment of nutrition in dialysis patients. Nephrol Dial Transplant. 1993; 8(10):1094-8. View

5.
Breborowicz A, Oreopoulos D . Biocompatibility of peritoneal dialysis solutions. Am J Kidney Dis. 1996; 27(5):738-43. DOI: 10.1016/s0272-6386(96)90114-6. View